BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 21033230)

  • 1. The application of Montreal classification in different clinical and serological IBD subtypes.
    Mokrowiecka A; Kumor A; Jakubczyk E; Pietruczuk M; Malecka-Panas E
    Hepatogastroenterology; 2010; 57(101):787-93. PubMed ID: 21033230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease.
    Peeters M; Joossens S; Vermeire S; Vlietinck R; Bossuyt X; Rutgeerts P
    Am J Gastroenterol; 2001 Mar; 96(3):730-4. PubMed ID: 11280542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Assessment of usefulness of anti-Saccharomyces cerevisiae and anti-neutrophil cytoplasmic antibodies in patients with unspecific inflammatory bowel diseases].
    Mokrowiecka A; Gasiorowska A; Małecka-Panas E
    Pol Merkur Lekarski; 2004; 17 Suppl 1():22-6. PubMed ID: 15603341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. pANCA and ASCA in the diagnosis of different subtypes of inflammatory bowel disease.
    Mokrowiecka A; Gasiorowska A; Malecka-Panas E
    Hepatogastroenterology; 2007; 54(77):1443-8. PubMed ID: 17708273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serological markers (anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic antibodies) in inflammatory bowel disease: diagnostic utility and phenotypic correlation.
    Buckland MS; Mylonaki M; Rampton D; Longhurst HJ
    Clin Diagn Lab Immunol; 2005 Nov; 12(11):1328-30. PubMed ID: 16275949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort.
    Papp M; Altorjay I; Dotan N; Palatka K; Foldi I; Tumpek J; Sipka S; Udvardy M; Dinya T; Lakatos L; Kovacs A; Molnar T; Tulassay Z; Miheller P; Norman GL; Szamosi T; Papp J; ; Lakatos PL
    Am J Gastroenterol; 2008 Mar; 103(3):665-81. PubMed ID: 18047543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between ANCA and clinical activity in inflammatory bowel disease: variation in prevalence of ANCA and evidence of heterogeneity.
    Abad E; Tural C; Mirapeix E; Cuxart A
    J Autoimmun; 1997 Apr; 10(2):175-80. PubMed ID: 9185879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features.
    Annese V; Piepoli A; Perri F; Lombardi G; Latiano A; Napolitano G; Corritore G; Vandewalle P; Poulain D; Colombel JF; Andriulli A
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1143-52. PubMed ID: 15569117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype.
    Tarrant KM; Barclay ML; Frampton CM; Gearry RB
    Am J Gastroenterol; 2008 Dec; 103(12):3082-93. PubMed ID: 19086959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies: serologic markers in inflammatory bowel disease.
    Hartman C; Eliakim R; Shamir R
    Isr Med Assoc J; 2004 Apr; 6(4):221-6. PubMed ID: 15115261
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunological markers anti-saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: a helpful diagnostic tool.
    Montanelli A; Mainardi E; Vagni A; Villanacci V; Zambelli C; Cestari R; Cengia P; Minelli L; Missale G
    Minerva Gastroenterol Dietol; 2005 Jun; 51(2):201-7. PubMed ID: 15990710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype.
    Seow CH; Stempak JM; Xu W; Lan H; Griffiths AM; Greenberg GR; Steinhart AH; Dotan N; Silverberg MS
    Am J Gastroenterol; 2009 Jun; 104(6):1426-34. PubMed ID: 19491856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease.
    Dubinsky MC; Ofman JJ; Urman M; Targan SR; Seidman EG
    Am J Gastroenterol; 2001 Mar; 96(3):758-65. PubMed ID: 11280547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies in inflammatory bowel diseases.
    Kiliç ZM; Tunç B; Ayaz S; Filik L; Aktaş S; Parlak E; Ulker A
    Turk J Gastroenterol; 2004 Dec; 15(4):238-42. PubMed ID: 16249978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease.
    Bansi DS; Chapman RW; Fleming KA
    Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):881-5. PubMed ID: 8889455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease.
    Koutroubakis IE; Petinaki E; Mouzas IA; Vlachonikolis IG; Anagnostopoulou E; Castanas E; Maniatis AN; Kouroumalis EA
    Am J Gastroenterol; 2001 Feb; 96(2):449-54. PubMed ID: 11232689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of serological markers in inflammatory bowel disease.
    Mokrowiecka A; Daniel P; Słomka M; Majak P; Malecka-Panas E
    Hepatogastroenterology; 2009; 56(89):162-6. PubMed ID: 19453050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies to Escherichia coli outer membrane porin C in the absence of anti-Saccharomyces cerevisiae antibodies and anti-neutrophil cytoplasmic antibodies are an unreliable marker of Crohn disease and ulcerative colitis.
    Davis MK; Andres JM; Jolley CD; Novak DA; Haafiz AB; González-Peralta RP
    J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):409-13. PubMed ID: 18030205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of the Montreal classification for inflammatory bowel diseases.
    Spekhorst LM; Visschedijk MC; Alberts R; Festen EA; van der Wouden EJ; Dijkstra G; Weersma RK;
    World J Gastroenterol; 2014 Nov; 20(41):15374-81. PubMed ID: 25386087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory bowel diseases: controversies in the use of diagnostic procedures.
    Vucelic B
    Dig Dis; 2009; 27(3):269-77. PubMed ID: 19786751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.